trending Market Intelligence /marketintelligence/en/news-insights/trending/9ahn4x6tnjczkafwfmgp8q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

INSYS Therapeutics' painkiller spray rejected by US FDA over safety concerns

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


INSYS Therapeutics' painkiller spray rejected by US FDA over safety concerns

INSYS Therapeutics Inc. said the U.S. Food and Drug Administration rejected its application to market a buprenorphine spray as a treatment for moderate-to-severe acute pain.

The company received a complete response letter from the regulator flagging potential safety concerns for the spray, which is applied under the tongue.

The Chandler, Ariz.-based company added that the letter indicated that the buprenorphine spray was statistically significantly different than placebo in providing pain relief.

The FDA's decision comes after the agency's expert panel voted in May not to recommend the approval of the therapy.

Steve Sherman, INSYS Therapeutics' senior vice president of regulatory affairs, said the company is in the process of assessing its next steps.